Kyverna: miv-cel improved mobility 49% at one year in stiff person syndrome, FDA filing planned

Kyverna Therapeutics' one-year KYSA-8 data showed miv-cel improved mobility by a median 49% in stiff person syndrome, and the company plans to take the data to the FDA by year-end. It also reported longer-term follow-up from Phase 2 KYSA-6 in generalized myasthenia gravis.

Detected & updated continuously · Source: Nebula